Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Breast Carcinoma
|
2793 | 0.672 | 0.360 | 10 | 102837395 | 5 prime UTR variant | A/G;T | snv | 0.40; 8.1E-06 | 0.090 | 0.889 | 9 | 2008 | 2018 | |||||
Malignant neoplasm of breast
|
3417 | 0.672 | 0.360 | 10 | 102837395 | 5 prime UTR variant | A/G;T | snv | 0.40; 8.1E-06 | 0.090 | 0.889 | 9 | 2008 | 2018 | |||||
Malignant neoplasm of prostate
|
1082 | 0.672 | 0.360 | 10 | 102837395 | 5 prime UTR variant | A/G;T | snv | 0.40; 8.1E-06 | 0.050 | 0.800 | 5 | 2007 | 2015 | |||||
Prostate carcinoma
|
1168 | 0.672 | 0.360 | 10 | 102837395 | 5 prime UTR variant | A/G;T | snv | 0.40; 8.1E-06 | 0.050 | 0.800 | 5 | 2007 | 2015 | |||||
Alzheimer's Disease
|
1843 | 0.672 | 0.360 | 10 | 102837395 | 5 prime UTR variant | A/G;T | snv | 0.40; 8.1E-06 | 0.020 | 1.000 | 2 | 2014 | 2016 | |||||
Endometrial Carcinoma
|
326 | 0.672 | 0.360 | 10 | 102837395 | 5 prime UTR variant | A/G;T | snv | 0.40; 8.1E-06 | 0.020 | 1.000 | 2 | 2008 | 2013 | |||||
Endometriosis
|
274 | 0.672 | 0.360 | 10 | 102837395 | 5 prime UTR variant | A/G;T | snv | 0.40; 8.1E-06 | 0.020 | 0.500 | 2 | 2013 | 2018 | |||||
Malignant neoplasm of endometrium
|
197 | 0.672 | 0.360 | 10 | 102837395 | 5 prime UTR variant | A/G;T | snv | 0.40; 8.1E-06 | 0.020 | 1.000 | 2 | 2008 | 2013 | |||||
Anxiety
|
287 | 0.672 | 0.360 | 10 | 102837395 | 5 prime UTR variant | A/G;T | snv | 0.40; 8.1E-06 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Anxiety Disorders
|
163 | 0.672 | 0.360 | 10 | 102837395 | 5 prime UTR variant | A/G;T | snv | 0.40; 8.1E-06 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Benign Prostatic Hyperplasia
|
91 | 0.672 | 0.360 | 10 | 102837395 | 5 prime UTR variant | A/G;T | snv | 0.40; 8.1E-06 | 0.010 | 1 | 2019 | 2019 | ||||||
Breast Diseases
|
6 | 0.672 | 0.360 | 10 | 102837395 | 5 prime UTR variant | A/G;T | snv | 0.40; 8.1E-06 | 0.010 | 1.000 | 1 | 2008 | 2008 | |||||
Breast Fibrocystic Disease
|
12 | 0.672 | 0.360 | 10 | 102837395 | 5 prime UTR variant | A/G;T | snv | 0.40; 8.1E-06 | 0.010 | 1.000 | 1 | 2008 | 2008 | |||||
Gallbladder Carcinoma
|
75 | 0.672 | 0.360 | 10 | 102837395 | 5 prime UTR variant | A/G;T | snv | 0.40; 8.1E-06 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Hormone refractory prostate cancer
|
29 | 0.672 | 0.360 | 10 | 102837395 | 5 prime UTR variant | A/G;T | snv | 0.40; 8.1E-06 | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||
Liver carcinoma
|
942 | 0.672 | 0.360 | 10 | 102837395 | 5 prime UTR variant | A/G;T | snv | 0.40; 8.1E-06 | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||
Malignant neoplasm of gallbladder
|
81 | 0.672 | 0.360 | 10 | 102837395 | 5 prime UTR variant | A/G;T | snv | 0.40; 8.1E-06 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Menopausal symptom
|
4 | 0.672 | 0.360 | 10 | 102837395 | 5 prime UTR variant | A/G;T | snv | 0.40; 8.1E-06 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Ovarian Failure, Premature
|
115 | 0.672 | 0.360 | 10 | 102837395 | 5 prime UTR variant | A/G;T | snv | 0.40; 8.1E-06 | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||
Stage 0 Gallbladder Cancer AJCC v8
|
56 | 0.672 | 0.360 | 10 | 102837395 | 5 prime UTR variant | A/G;T | snv | 0.40; 8.1E-06 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Stage IIA Gallbladder Cancer AJCC v8
|
56 | 0.672 | 0.360 | 10 | 102837395 | 5 prime UTR variant | A/G;T | snv | 0.40; 8.1E-06 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Stage IIB Gallbladder Cancer AJCC v8
|
56 | 0.672 | 0.360 | 10 | 102837395 | 5 prime UTR variant | A/G;T | snv | 0.40; 8.1E-06 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Stage III Gallbladder Cancer AJCC v8
|
56 | 0.672 | 0.360 | 10 | 102837395 | 5 prime UTR variant | A/G;T | snv | 0.40; 8.1E-06 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Stage IV Gallbladder Cancer AJCC v8
|
56 | 0.672 | 0.360 | 10 | 102837395 | 5 prime UTR variant | A/G;T | snv | 0.40; 8.1E-06 | 0.010 | 1.000 | 1 | 2014 | 2014 |